DK0930883T3 - Neurotrofinantagonister til behandling af epilepsi, Alzheimers sygdom og smerte - Google Patents
Neurotrofinantagonister til behandling af epilepsi, Alzheimers sygdom og smerteInfo
- Publication number
- DK0930883T3 DK0930883T3 DK97909098T DK97909098T DK0930883T3 DK 0930883 T3 DK0930883 T3 DK 0930883T3 DK 97909098 T DK97909098 T DK 97909098T DK 97909098 T DK97909098 T DK 97909098T DK 0930883 T3 DK0930883 T3 DK 0930883T3
- Authority
- DK
- Denmark
- Prior art keywords
- loweralkyl
- neurotrophin
- carboxy
- optionally substituted
- epilepsy
- Prior art date
Links
- 108010025020 Nerve Growth Factor Proteins 0.000 title abstract 3
- 102000007072 Nerve Growth Factors Human genes 0.000 title abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 208000002193 Pain Diseases 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 206010015037 epilepsy Diseases 0.000 title 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 125000001769 aryl amino group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000014511 neuron projection development Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/14—Aza-phenalenes, e.g. 1,8-naphthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9621902.7A GB9621902D0 (en) | 1996-10-21 | 1996-10-21 | Neurotrophin antagonist compositions |
| GBGB9710904.5A GB9710904D0 (en) | 1997-05-27 | 1997-05-27 | Neurotropin antagonist compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0930883T3 true DK0930883T3 (da) | 2006-05-22 |
Family
ID=26310264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK97909098T DK0930883T3 (da) | 1996-10-21 | 1997-10-20 | Neurotrofinantagonister til behandling af epilepsi, Alzheimers sygdom og smerte |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US20020169182A1 (da) |
| EP (1) | EP0930883B1 (da) |
| JP (1) | JP2001503397A (da) |
| KR (1) | KR20000052691A (da) |
| AT (1) | ATE315397T1 (da) |
| AU (1) | AU728523C (da) |
| BR (1) | BR9712424A (da) |
| CA (1) | CA2268450C (da) |
| DE (1) | DE69735090T2 (da) |
| DK (1) | DK0930883T3 (da) |
| ES (1) | ES2257768T3 (da) |
| IL (1) | IL129475A0 (da) |
| NZ (1) | NZ335291A (da) |
| WO (1) | WO1998017278A1 (da) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001503397A (ja) | 1996-10-21 | 2001-03-13 | アレリックス バイオファーマシューティカルズ インコーポレイテッド | ニューロトロフィンアンタゴニスト組成物 |
| AU760136B2 (en) * | 1998-11-25 | 2003-05-08 | Merck Patent Gmbh | Substituted benzo(DE)isoquinoline-1,3-diones |
| PL347766A1 (en) * | 1998-11-25 | 2002-04-22 | Merck Patent Gmbh | Substituted benzo[de]isoquinoline-1,3-diones |
| US6468990B1 (en) | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
| US6492380B1 (en) * | 1999-05-17 | 2002-12-10 | Queen's University At Kingston | Method of inhibiting neurotrophin-receptor binding |
| FR2807660A1 (fr) * | 2000-04-13 | 2001-10-19 | Warner Lambert Co | Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques |
| UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
| PL211654B1 (pl) | 2002-10-08 | 2012-06-29 | Rinat Neuroscience Corp | Przeciwciało skierowane przeciwko NGF do zastosowania w leczeniu bólu pooperacyjnego, zastosowanie tego przeciwciała do wytwarzania leku do leczenia bólu pooperacyjnego i kompozycja farmaceutyczna zawierająca przeciwciało skierowane przeciwko NGF do zastosowania w leczeniu bólu pooperacyjnego |
| NZ540730A (en) | 2002-12-24 | 2010-09-30 | Rinat Neuroscience Corp | Anti-NGF antibodies and methods using same |
| US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
| US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| NZ541750A (en) | 2003-02-19 | 2008-11-28 | Rinat Neuroscience Corp | Use of an anti-nerve growth factor antibody and an NSAID for the preparation of a medicament for treating pain |
| FR2862968B1 (fr) * | 2003-12-01 | 2006-08-04 | Sanofi Synthelabo | Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique |
| FR2862967B1 (fr) * | 2003-12-01 | 2006-08-04 | Sanofi Synthelabo | Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique |
| SG152226A1 (en) | 2004-04-07 | 2009-05-29 | Rinat Neuroscience Corp | Methods for treating bone cancer pain by administering a nerve growth factor antagonist |
| GB0419850D0 (en) * | 2004-09-07 | 2004-10-13 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| CA2622574A1 (en) | 2005-09-15 | 2007-03-22 | Painceptor Pharma Corporation | Methods of modulating neurotrophin-mediated activity |
| WO2009039635A1 (en) * | 2007-09-24 | 2009-04-02 | Painceptor Pharma Corporation | Methods of modulating neurotrophin-mediated activity |
| FR2953839A1 (fr) | 2009-12-14 | 2011-06-17 | Sanofi Aventis | Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75 |
| HRP20220405T1 (hr) | 2010-08-19 | 2022-05-27 | Zoetis Belgium S.A. | Protutijela protiv ngf i njihova upotreba |
| EP2606894A1 (en) | 2011-12-20 | 2013-06-26 | Sanofi | Novel therapeutic use of p75 receptor antagonists |
| AU2013271564A1 (en) | 2012-06-06 | 2014-12-04 | Zoetis Services Llc | Caninized anti-NGF antibodies and methods thereof |
| JP2021517461A (ja) | 2018-03-12 | 2021-07-26 | ゾエティス・サービシーズ・エルエルシー | 抗ｎｇｆ抗体およびその方法 |
| BR112023001238A2 (pt) * | 2020-07-24 | 2023-04-04 | Jawaharlal Nehru Centre For Advanced Scient Research | Compostos de monoimida de naftaleno e métodos para os mesmos |
| WO2023212596A1 (en) | 2022-04-27 | 2023-11-02 | Regeneron Pharmaceuticals, Inc. | Treatment of arthropathy based upon stratification of osteoarthritis polygenic risk score |
| WO2024196744A1 (en) | 2023-03-17 | 2024-09-26 | Regeneron Pharmaceuticals, Inc. | Proteomic risk score for osteoarthritis (oa) |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US627129A (en) * | 1899-06-20 | Collar-edge-ironing machine | ||
| US525841A (en) * | 1894-09-11 | Baling-press | ||
| US3821383A (en) * | 1972-07-10 | 1974-06-28 | Ayerst Mckenna & Harrison | Compositions for and a method of treating diabetic complications |
| US4006238A (en) | 1975-08-28 | 1977-02-01 | E. R. Squibb & Sons, Inc. | Use of 2-(hydroxyalkyl)-1H-benz[de]isoquinoline-1,3(2H)-diones as anti-allergy agents |
| ES459497A1 (es) | 1977-06-04 | 1978-04-16 | Made Labor Sa | Un metodo para la preparacion industrial de naftalimidas y sus derivados. |
| US4254109A (en) * | 1979-11-08 | 1981-03-03 | Ayerst, Mckenna & Harrison Inc. | 1H-Benz[de]isoquinoline-2(3H)-acetic acid derivatives |
| RU2051677C1 (ru) * | 1982-02-10 | 1996-01-10 | Украинский научно-исследовательский институт эндокринологии и обмена веществ | Средство для профилактики и лечения диабетических осложнений, ангиопатий, нейропатий, катаракты |
| US5183821A (en) | 1983-09-19 | 1993-02-02 | Laboratories Knoll, S.A. | Method for treating leukemias using N-(2-dimethylaminoethyl)-3-amino-1,8-naphthalimide for treating leukemias and solid tumors |
| IT1214618B (it) * | 1985-06-27 | 1990-01-18 | I P A International Pharmaceut | Composti e composizioni farmaceutiche per la terapia di retinopatie e neuropatie diabetiche. |
| DE3635711A1 (de) | 1986-10-21 | 1988-04-28 | Knoll Ag | 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung |
| DE3707651A1 (de) | 1987-03-10 | 1988-09-22 | Knoll Ag | Bis-naphthalimide, ihre herstellung und verwendung |
| DE3707652A1 (de) * | 1987-03-10 | 1988-09-22 | Knoll Ag | Verwendung von benzo(de)isochinolin-1,3-dionen zur herstellung von arzneimitteln |
| US5420137A (en) | 1989-07-11 | 1995-05-30 | Knoll Ag | Amonafide salts |
| US5356906A (en) * | 1989-10-27 | 1994-10-18 | The Du Pont Merck Pharmaceutical Company | (N-phthalimidoalkyl) piperidines useful as treatments for psychosis |
| CA2030129A1 (en) | 1989-11-29 | 1991-05-30 | Thomas Saupe | 1,8-napthalenedicarboximides as antidotes |
| US5342942A (en) | 1992-06-09 | 1994-08-30 | Warner-Lambert Company | Pyrazoloquinazolone derivatives as neurotrophic agents |
| DE4232739A1 (de) | 1992-09-30 | 1994-03-31 | Knoll Ag | Neue asymmetrisch substituierte bis-Naphthalimide |
| IL110460A (en) | 1993-08-18 | 2001-01-11 | Basf Ag | Bite-naphthalimides, their preparation and pharmaceutical preparations containing them |
| US6291247B1 (en) | 1994-05-11 | 2001-09-18 | Queen's University At Kingston | Methods of screening for factors that disrupt neurotrophin conformation and reduce neurotrophin biological activity |
| GB9616105D0 (en) | 1996-07-31 | 1996-09-11 | Univ Kingston | TrkA binding site of NGF |
| JP2001503397A (ja) | 1996-10-21 | 2001-03-13 | アレリックス バイオファーマシューティカルズ インコーポレイテッド | ニューロトロフィンアンタゴニスト組成物 |
| DK1093819T3 (da) | 1997-02-07 | 2006-09-11 | Emisphere Tech Inc | Forbindelse og præparat til tilförsel af aktive midler |
| AU7449198A (en) | 1997-05-21 | 1998-12-11 | Japan Tobacco Inc. | Phthalimide derivatives and pharmaceutical containing said derivatives |
| AU4698299A (en) | 1998-06-30 | 2000-01-17 | Du Pont Pharmaceuticals Company | 5-HT7 receptor antagonists |
| KR100364205B1 (ko) | 1998-07-03 | 2002-12-11 | 다이호야쿠힌고교 가부시키가이샤 | 나프탈이미도벤즈아미드 유도체 또는 그의 염 |
| US6468990B1 (en) | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
| US6492380B1 (en) | 1999-05-17 | 2002-12-10 | Queen's University At Kingston | Method of inhibiting neurotrophin-receptor binding |
-
1997
- 1997-10-20 JP JP51875698A patent/JP2001503397A/ja not_active Ceased
- 1997-10-20 AT AT97909098T patent/ATE315397T1/de not_active IP Right Cessation
- 1997-10-20 IL IL12947597A patent/IL129475A0/xx not_active IP Right Cessation
- 1997-10-20 NZ NZ335291A patent/NZ335291A/en unknown
- 1997-10-20 BR BR9712424-9A patent/BR9712424A/pt not_active Application Discontinuation
- 1997-10-20 ES ES97909098T patent/ES2257768T3/es not_active Expired - Lifetime
- 1997-10-20 DK DK97909098T patent/DK0930883T3/da active
- 1997-10-20 KR KR1019990703479A patent/KR20000052691A/ko not_active Application Discontinuation
- 1997-10-20 EP EP97909098A patent/EP0930883B1/en not_active Expired - Lifetime
- 1997-10-20 WO PCT/CA1997/000779 patent/WO1998017278A1/en active IP Right Grant
- 1997-10-20 CA CA002268450A patent/CA2268450C/en not_active Expired - Fee Related
- 1997-10-20 DE DE69735090T patent/DE69735090T2/de not_active Expired - Fee Related
- 1997-10-20 AU AU46968/97A patent/AU728523C/en not_active Ceased
-
2001
- 2001-01-11 US US09/758,917 patent/US20020169182A1/en not_active Abandoned
-
2005
- 2005-07-13 US US11/179,610 patent/US7291629B2/en not_active Expired - Fee Related
-
2007
- 2007-09-28 US US11/905,406 patent/US20080287484A1/en not_active Abandoned
-
2009
- 2009-04-28 US US12/453,032 patent/US20090215815A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP0930883A1 (en) | 1999-07-28 |
| JP2001503397A (ja) | 2001-03-13 |
| EP0930883B1 (en) | 2006-01-11 |
| ES2257768T3 (es) | 2006-08-01 |
| US20050250807A1 (en) | 2005-11-10 |
| US20090215815A1 (en) | 2009-08-27 |
| DE69735090T2 (de) | 2006-09-14 |
| WO1998017278A1 (en) | 1998-04-30 |
| NZ335291A (en) | 2001-02-23 |
| US7291629B2 (en) | 2007-11-06 |
| DE69735090D1 (de) | 2006-04-06 |
| US20020169182A1 (en) | 2002-11-14 |
| BR9712424A (pt) | 2001-11-20 |
| AU4696897A (en) | 1998-05-15 |
| KR20000052691A (ko) | 2000-08-25 |
| ATE315397T1 (de) | 2006-02-15 |
| CA2268450C (en) | 2008-08-05 |
| AU728523C (en) | 2001-08-09 |
| CA2268450A1 (en) | 1998-04-30 |
| IL129475A0 (en) | 2000-02-29 |
| US20080287484A1 (en) | 2008-11-20 |
| AU728523B2 (en) | 2001-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0930883T3 (da) | Neurotrofinantagonister til behandling af epilepsi, Alzheimers sygdom og smerte | |
| HK1094191A1 (en) | Phenyl-carboxamide compounds useful for treating pain | |
| DE69531502D1 (de) | Monoamid, diamid, thiol enthaltende metall-chelatierende verbindungen | |
| MX9709416A (es) | Compuesto tipo quinolizinona. | |
| DK0652005T3 (da) | Fremgangsmåder til inhibering af endometriose | |
| IL129238A0 (en) | N-(aryl/heteroarylacetyl) amino acid esters pharmaceutical compositions comprising same and methods for inhibiting b-amyloid peptide release and/ or its synthesis by use of such compounds | |
| WO2005056524A3 (en) | Therapeutic agents useful for treating pain | |
| MY135057A (en) | Dolastatin 15 derivatives | |
| WO1998046576A3 (en) | Halo-alkoxycarbonyl prodrugs | |
| DK0652002T3 (da) | Anvendelse af 2-phenyl-3-aroylebenzothiophener til fremstilling af et medikament til hæmning af brusknedbrydning | |
| DK0659427T3 (da) | 2-Phenyl-3-azoylbenzothiophener til forøgelse af thrombomodulinekspression | |
| YU69699A (sh) | Derivati aril karbonske kiseline i tetrazola | |
| DE69810332D1 (de) | Antibakterielle carbapeneme, zusammensetzungen und verfahren zur behandlung | |
| AU5270696A (en) | Novel heterocyclic compounds | |
| DE69622393D1 (de) | Neue verwendung von pyrazolopyridinverbindungen | |
| RU97104066A (ru) | Сочетание ингибиторов вич-протеазы | |
| MX9701528A (es) | Derivados de 1, 1, 2,- trifenilbut-1-eno para tratar la enfermedad de alzheimer. | |
| MX9703610A (es) | Nuevas (5,6)-heteroaril condensado-pirimidin-4-onas 2,3 disustituidas. |